Although ST3GalI expression is elevated in 90% of breast cancers [16], the ST glycan is found in ∼50% of these cancers due to competition with C2GNT, which is only lost in a proportion of breast cancers [16]. Here, ST3GAL1 is linked to breast carcinoma.